Advertisement


Alan F. List, MD, on Sotatercept in Lower-Risk Myelodysplastic Syndromes

2014 ASH Annual Meeting

Advertisement

Alan F. List, MD, of Moffitt Cancer Center, offers his thoughts on abstract 3251, “An Open-Label, Phase II, Dose-Finding Study of Sotatercept (ACE-011) in Patients With Low or Intermediate-1–Risk Myelodysplastic Syndromes or Nonproliferative Chronic Myelomonocytic Leukemia and Anemia Requiring Transfusion,” presented by Rami S. Komrokji, MD.



Related Videos

Hematologic Malignancies

Keith McCrae, MD, on Caplacizumab in Thrombotic Thrombocytopenic Purpura

Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 229, “Caplacizumab, ...

Hematologic Malignancies

Keith McCrae, MD, on Managing Heparin-Induced Thrombocytopenia

Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 4848, “Implementatio...

Myelodysplastic Syndromes

Alan F. List, MD, on Rigosertib in Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome

Alan F. List, MD, of Moffitt Cancer Center, offers his thoughts on abstract 163, “Overall Survi...

Multiple Myeloma

Sagar Lonial, MD, on Monoclonal Antibodies in Multiple Myeloma

Sagar Lonial, MD, of Winship Cancer Institute, offers his thoughts on abstract 302, “Final Resu...

Lymphoma

Julie M. Vose, MD, MBA, FASCO, on the AETHERA trial

Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 673,


Advertisement



Advertisement